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disease management program. As such, future efforts should be
developed to increase retention in disease management programs
designed for Medicaid recipients.
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OBJECTIVE: To evaluate the effect of insulin treatment on
health care utilization among type-II diabetics. More aggressive
glucose control treatment, particularly with insulin, is known to
slow diabetic patients’ disease progression. Does it also reduce
health care utilization and cost in the short run? METHODS:
Medical, pharmacy, and laboratory claims for 369 type-II dia-
betes patients enrolled in a single managed care plan were eval-
uated. Patients were continuously eligible for at least two years
between June, 2001 and June, 2004. Separate variables were
computed for each year. The propensity score (PS) calculated
with classiﬁcation and regression trees (C&RT) was used to cal-
culate the probability of receiving insulin treatment, using year
one health status, demographics, and HgA1c laboratory values.
These probabilities were then used as weights in the regression
of total health care costs and ambulatory costs in year two on
an array of variables including insulin use. RESULTS: Insulin
treatment does not beneﬁt all groups of patients equally. Patients
over the age of 60 beneﬁt signiﬁcantly from insulin treatment
with a reduction in total health care cost of 60.5% (p = 0.0007)
and a reduction in ambulatory cost of 60.9% (p = 0.0008) com-
pared to younger diabetic patients (age < 60). CONCLUSION:
Diabetic patients age 60 or above and the health care payers
would greatly beneﬁt from better glucose control through insulin
treatment.
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OBJECTIVES: Diabetes is a progressive disease that often
requires periodic intensiﬁcation of treatment to control hyper-
glycemia. The objective of this study is to evaluate therapy
changes after initiation of metformin and sulfonylurea combi-
nation therapy. METHODS: This was a retrospective analysis of
data derived from the IMS Mediplus UK primary care database.
Patients were selected using the following criteria: type-2 dia-
betes diagnosis, age ≥30 years at diagnosis, initiation of OHA
combination with MF and SU between January 1, 1997 and
March 31, 2003. Patients with prior insulin prescription were
excluded. RESULTS: A toal of 6616 patients were included, with
a mean age of 62.82 years (±12.12) and 56.3% of male; 2603
patients (39.39%) had a history of macrovascular events and
647 (9.79%) had microvascular events. Hypertension (78.39%)
and dyslipidemia (59.89%) were also common among these
patients. The average follow-up was about 36.7 months. After
three years of initiating metformin and sulfonylurea combination
therapy, 54.8% had changed their therapy, either by discontin-
uing one or both initial agents, adding a third oral agent or
receiving insulin. No patient remained on the initial combination
after 6.5 years. Approximately 8–11% of patients changed
therapy every six-months during the ﬁrst ﬁve-years. By the end
of two years, about 14.1% have required insulin therapy and
10% had switched to another OHA combination therapy.
Approximately 46.9% of patients were prescribed insulin
therapy after seven-years. CONCLUSION: In this cohort of 
diabetic patients managed by GPs in the UK, a large number 
of patients require additional oral anti-hyperglycemic agents or
insulin to manage their hyperglycemia. More effective therapies
are needed in order to better manage these patients.
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OBJECTIVE: To investigate factors associated with health care
cost saving in patients with diabetes to the California Medicaid
Populations (Medi-Cal). METHODS: A retrospective study was
conducted by using claims data from January, 1995 to Decem-
ber, 2000. Dependent variable was total health care cost. His-
torical data including demographic factors, health care cost and
utilization, diabetes drug treatment, follow-up services based on
diabetic guidelines, medication compliance, complications, and
comorbidities were used as independent variables. The general-
ized estimating equation method was used to analyze the panel
data. RESULTS: Various factors have a signiﬁcant association
with health care cost savings to MediCal. Patients taking both
insulin and oral hypoglycemic drugs or patients having drug dose
increased had health care costs higher by $1210 and $141,
respectively. Patients having oral hypoglycemic or insulin, anti-
hypertensive, or lipid lowering drugs added also had health care
costs higher by $264, $528, or $199, respectively. In addition,
patients having drugs changed to different classes or to insulin
had health care costs higher by $1018. However, patients having
one percent of medication compliance increased had health care
costs lower by $7 in next six-month period. Moreover, patients
having ofﬁce visits based on diabetic guidelines or patients
having glucose monitoring strip had health care costs lower by
$730 or $258 in next six-month period, respectively. In addition,
patients having lab tests [e.g., HbA1C test every six-months
($121), cholesterol check up every year ($472), or dilated eye
check-up every year ($260)] could lower costs in the future.
CONCLUSIONS: Medi-Cal policy makers may implement some
disease management programs or health policy on patients who
have drug treatment problems and patients without follow-up
services based on diabetic guidelines in order to improve patient
outcomes and decrease health care costs in the future.
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OBJECTIVE: To examine the relationship between patient’s
payment type and prescription drug costs for diabetic outpatients
at a regional hospital in southern Thailand. METHODS:
Patient’s proﬁle and prescription for 1454 outpatients who used
anti-diabetic drugs between August and September 2002 were
collected. The patient’s type of payment was divided into two
groups, which were patients who paid out-of-pocket and patients
who did not pay for their prescriptions. Descriptive and linear
regression analyses were used to examine the relationship.
RESULTS: Results showed that average drug costs per prescrip-
tion between patients who paid out-of-pocket and patients who
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did not pay for their prescriptions were signiﬁcantly different 
(p < 0.05). The average anti-diabetic drug cost of the patients
who paid out-of-pocket was 643.38 Baht ($US 1 = 40Baht) and
their average total drug cost was 1853.12 Baht, while the average
anti-diabetic drug cost of the patients who did not pay for their
prescriptions was 437.91 Baht and their average total drug cost
was 990.94 Baht. In drug cost per day basis, the results showed
that the average anti-diabetic drug costs per day between two
patient groups were not signiﬁcantly different (p > 0.05).
However, their average total drug costs per day were signiﬁcantly
different (p < 0.05). The average total drug cost per day of the
patients who paid out-of-pocket was 26.76 Baht, while it was
17.56 Baht for the patients who did not pay for their prescrip-
tions. Linear regression results showed that the patient’s type of
payment signiﬁcantly inﬂuenced both anti-diabetic and total
drug cost per prescription and cost per day. CONCLUSIONS: A
signiﬁcant relationship between patient’s payment type and pre-
scription drug costs for diabetic patients was found. The patients
who paid out-of-pocket likely obtained more expensive pre-
scription drugs than did the patients who did not pay for their
prescriptions.
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OBJECTIVE: To examine prescribing trends of combination oral
hypoglycemic therapy for persons with Type-II diabetes using
prescription claims. METHODS: Prescribing trends were identi-
ﬁed for patients using combination oral hypoglycemic agents for
the treatment of diabetes during a three month period beginning
November, 2003–January, 2004. Persons were considered newly
treated with type II diabetes if there were no prescription claims
for insulin or oral diabetes agents during a three month period
prior to the ﬁrst prescription for a combination product. Trends
in patients already receiving oral hypoglycemic agents or insulin
were identiﬁed if combination therapy was added after mini-
mally three months of therapy or if oral hypoglycemic combi-
nation therapy was added to an existing treatment regimen
during the three-month observation period. Current recommen-
dations for use of combination therapy were compared to the
results of prescribing trends obtained from administrative data.
RESULTS: On average, approximately 661,811 persons were
identiﬁed with combination therapy on a monthly basis (211,922
in November, 2003; 227,981 in December, 2003; 221,908 in
January, 2004). Of these, on average approximately 130,708
received metformin/rosiglitazone, 491,380 received metformin/
glyburide, and 38,011 received metformin/glipizide. Several pre-
scribing trends were observed for these agents. Despite literature
to the contrary, the combination metformin/rosiglitazone was
prescribed as initial therapy for 19% of patients receiving pre-
scriptions for that product. Combination products were pre-
scribed as initial therapy for 11% to 19% of patients depending
on product. Almost 1% of patients received a combination
product plus two or more agents on a monthly basis. A small
number of patients received two combination products in their
daily regimen. CONCLUSION: Approximately one-ﬁfth of
patients receive initial oral hypoglycemic therapy outside of
current prescribing recommendations. The prescribing patterns
observed from this data suggest the need for treatment regimen
management and for plans to carefully study the economic
impact of multiple regimen treatments.
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Objective: To quantify the incidence and risk of needlestick
injury (NI) in nurses caring for patients with diabetes.
METHODS: Four hundred nurses caring for patients with dia-
betes in 381 hospitals throughout the United States reported data
on their experience with NI, focusing on those occurring within
the past year. If respondents experienced multiple NI during this
period, detailed data were collected on the most recent event.
RESULTS: Of the 400 nurses, 313 (78.3%) reported having ever
had a NI, 110 (27.5%) reported having had a NI within the last
twelve months, and 44 (40% of those 110) reported multiple NI.
Nearly two-thirds of these injuries (n = 73; 66.4%) were punc-
tures that drew blood, resulting in one case of contracted hepati-
tis C. The cumulative annual incidence of NI events was 448 NI
per 1000 nurses. Nurses reported the injury in adherence with
existing policies in 21.8% of cases. Disposable syringes were
involved in 88 (80%) of the events. In half of the injuries (n =
55), the needled device was equipped with a safety feature that
was ineffective, primarily because it was not fully activated (n =
47; 85.5%) or it malfunctioned (n = 2 to 5; 3.6% to 9.1%). NI
most commonly occurred while nurses were injecting insulin 
(n = 33; 30%). In the two weeks following their NI, 60.1% of
nurses were more afraid of needled devices than before the injury
and 41.8% felt anxious, depressed, or stressed. As a direct result
of the NI, nurses missed 77 days of work. CONCLUSIONS: This
study is the ﬁrst to show the relatively high risk both of NI and
of NI that draws blood among nurses injecting insulin with a
disposable syringe. Additionally, this study reveals signiﬁcant
post-NI emotional distress, suggests signiﬁcant under-reporting
of NI to hospital ofﬁcials, and demonstrates the need for a more
effective needle safety device.
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OBJECTIVE: For patients with type-1 diabetes, having a pre-
ferred insulin delivery system may lead to better compliance and
better clinical and patient-reported outcomes. The purpose of
this study was to assess the reliability and validity of the Insulin
Delivery System Questionnaire (IDSQ), an instrument developed
to measure overall insulin satisfaction and preference for an
insulin delivery system. METHODS: The IDSQ was adminis-
tered to 137 patients with type-1 diabetes at screening, baseline,
crossover, and endpoint of a randomized, noninferiority,
crossover trial designed to compare the glycemic control of
injectable vs. inhaled insulin. Psychometric analyses included
internal consistency (Cronbach’s alpha), factorial validity (prin-
cipal component analysis with Promax rotation), discriminant
validity (ANCOVA model with baseline score and other covari-
ates), and responsiveness (t-tests). RESULTS: Exploratory factor
analysis indicated that there were three factors accounting for
73% of the variance. All items loaded above >0.50 on either
Factor one, lifestyle impact; Factor two, ease of dosing; or Factor
three, satisfaction/preference with the exception of the “easy to
control my blood sugar” (BG) item. Cronbach’s alpha coefﬁ-
cients calculated for the factors were 0.93, 0.86, and 0.86,
